SCHEMBL4479139

SCHEMBL4479139

CN(C)C(=O)c1c2c(c(O)c[n+]1[O-])C(=O)N(Cc1ccc(F)c(Cl)c1)CC2

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 1/20 0.33
ERCC1 P07992 1/20 0.33
ERCC4 Q92889 1/20 0.33
WDR5 P61964 1/20 0.33
HTR2A P28223 1/20 0.33
GRM2 Q14416 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
PIK3CA P42336 1/20 0.32
KCNH2 Q12809 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
TNIK Q9UKE5 1/20 0.32
FSCN1 Q16658 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5821665 0.92 GRIN2B (0.33) AKR1B1MAPK1GRM2KCNH2TNIK
SCHEMBL1337231 0.86 MEN1 (0.42) AKR1B1MEN1KMT2AWDR5SMN1; SMN2
SCHEMBL4480309 0.81 TNIK (0.37) AKR1B1MAPK1ERCC1ERCC4GRM2
SCHEMBL6031443 0.79 MEN1 (0.37) MEN1KMT2ACYP1A2CYP2C19TNIK
SCHEMBL31060990 0.79 AKR1B1 (0.36) AKR1B1MAPK1WDR5HTR2AGRM2
SCHEMBL4479511 0.79 AKR1B1 (0.36) AKR1B1MAPK1WDR5HTR2AGRM2
SCHEMBL4488414 0.79 AKR1B1 (0.35) AKR1B1MAPK1WDR5HTR2AGRM2
SCHEMBL4487029 0.78 AKR1B1 (0.36) AKR1B1MAPK1HTR2AGRM2PIK3CA
SCHEMBL1335730 0.78 AKR1B1 (0.36) AKR1B1MAPK1HTR2AGRM2PIK3CA
SCHEMBL4489034 0.78 AKR1B1 (0.38) AKR1B1MAPK1HTR2AGRM2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H AKR1B1 2248/4885MEN1 4754/4885KMT2A 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.